Document is current
Any future updates will be listed below
-
Authors
Nuttall Musson, Ellen https://orcid.org/0000-0002-0395-3304
Hoade, Yvette
Dace, Phoebe https://orcid.org/0000-0003-1475-3858
Herrero, Javier
Denaxas, Spiros
Steptoe, Andrew
Payne, Elspeth https://orcid.org/0000-0001-5841-778X
- License Information
-
More Information
Article History
Received: 10 April 2025
Revised: 10 November 2025
Accepted: 20 November 2025
First Online: 10 December 2025
Competing interests
: JH is employed by Asgard Therapeutics.
: Ethical approval for each ELSA wave was obtained as detailed. ELSA Wave 2 received ethical approval from the London Multi-Centre Research Ethics Committee on 12th August 2004 (MREC/04/2/006). ELSA Wave 4 received ethical approval from the National Hospital for Neurology and Neurosurgery & Institute of Neurology Joint Research Ethics Committee on 12th October 2007 (07/H0716/48). ELSA Wave 6 received ethical approval from the NRES Committee South Central - Berkshire on 28th November 2012 (11/SC/0374). ELSA Wave 8 received ethical approval from the South Central – Berkshire Research Ethics Committee on 23rd September 2015 (15/SC/0526). ELSA Wave 9 received ethical approval from the South Central – Berkshire Research Ethics Committee on 10th May 2018 (17/SC/0588). Informed consent was obtained from all participants and all methods were performed in accordance with the relevant guidelines and regulations.
